188 filings
8-K
KA
Kineta Inc
24 Apr 24
Entry into a Material Definitive Agreement
4:00pm
8-K
KA
Kineta Inc
18 Apr 24
Departure of Directors or Certain Officers
4:00pm
8-K
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
8-K
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
9f4dcg
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
n49d9a2
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
ju5ix32pa9u cjfkrj
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
asl0nlq
15 Dec 23
Entry into a Material Definitive Agreement
8:30am
8-K
w0rfne ke
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
s3zhtgkes
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
tzf2gzqmtvcpqi86eoz
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
btwh6710 d6oho2589e
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
7g1g87qxlb7ap2t7
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
p85uz76
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
eabftvua pue0cjny3
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
4uc39h3ub 0lf1sy
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
0zmbhbqiskz gtcjz
16 Aug 23
Other Events
4:00pm
8-K
v2mwhvf8 acnastvmu
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
65acp1jh3riravn2 1u7
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm